TLX101-CDx
Glioblastoma Imaging
Phase 3Active (GLIOMA)
Key Facts
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals is a global leader in radiopharmaceuticals, focusing on theranostics—a combined diagnostic and therapeutic approach for cancer. The company has achieved commercial success with its FDA-approved prostate cancer imaging agent, Illuccix®, and is advancing a deep clinical pipeline targeting renal, brain, and other cancers. With a vertically integrated platform spanning discovery to commercialization, Telix is strategically positioned to capture significant value in the high-growth precision oncology market.
View full company profileTherapeutic Areas
Other Glioblastoma Imaging Drugs
| Drug | Company | Phase |
|---|---|---|
| TLX101-CDx (123I-IPA) | Telix Pharmaceuticals | Phase 2/3 |